JP2000500479A5 - - Google Patents

Download PDF

Info

Publication number
JP2000500479A5
JP2000500479A5 JP1997519454A JP51945497A JP2000500479A5 JP 2000500479 A5 JP2000500479 A5 JP 2000500479A5 JP 1997519454 A JP1997519454 A JP 1997519454A JP 51945497 A JP51945497 A JP 51945497A JP 2000500479 A5 JP2000500479 A5 JP 2000500479A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997519454A
Other languages
English (en)
Other versions
JP2000500479A (ja
Filing date
Publication date
Priority claimed from FR9513956A external-priority patent/FR2741621B1/fr
Application filed filed Critical
Publication of JP2000500479A publication Critical patent/JP2000500479A/ja
Publication of JP2000500479A5 publication Critical patent/JP2000500479A5/ja
Pending legal-status Critical Current

Links

Description

Figure 2000500479
Figure 2000500479
Figure 2000500479
Figure 2000500479
Figure 2000500479
Figure 2000500479
Figure 2000500479
JP9519454A 1995-11-23 1996-11-21 ピラゾール誘導体、その製造方法、および該誘導体を含む医薬組成物 Pending JP2000500479A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR95/13956 1995-11-23
FR9513956A FR2741621B1 (fr) 1995-11-23 1995-11-23 Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
PCT/FR1996/001847 WO1997019063A1 (fr) 1995-11-23 1996-11-21 Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
JP2000500479A JP2000500479A (ja) 2000-01-18
JP2000500479A5 true JP2000500479A5 (ja) 2004-10-21

Family

ID=9484869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9519454A Pending JP2000500479A (ja) 1995-11-23 1996-11-21 ピラゾール誘導体、その製造方法、および該誘導体を含む医薬組成物

Country Status (16)

Country Link
US (1) US6028084A (ja)
EP (1) EP0876350B1 (ja)
JP (1) JP2000500479A (ja)
AT (1) ATE203015T1 (ja)
AU (1) AU7698596A (ja)
BR (1) BR9611618A (ja)
CA (1) CA2238430C (ja)
DE (1) DE69613860T2 (ja)
DK (1) DK0876350T3 (ja)
ES (1) ES2161382T3 (ja)
FR (1) FR2741621B1 (ja)
GR (1) GR3036830T3 (ja)
MX (1) MX9803891A (ja)
NO (1) NO310508B1 (ja)
PT (1) PT876350E (ja)
WO (1) WO1997019063A1 (ja)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041519A1 (en) * 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
DE69910373T2 (de) * 1998-05-04 2004-04-01 The University Of Connecticut, Farmington Analgetische und immunomodulierende cannabinoiden
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
MXPA02005103A (es) 1999-10-18 2003-09-25 Alexipharma Inc Ligandos selectivos del receptor de canabinoide (cb2) perifericos.
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US6974568B2 (en) * 2000-05-23 2005-12-13 The Regents Of The University Of California Treatment for cough
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
WO2002058636A2 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
CA2436133A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
JP4312594B2 (ja) * 2001-07-13 2009-08-12 ユニバーシティ オブ コネチカット 新規な二環式及び三環式カンナビノイド
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
CN1589269A (zh) * 2001-10-26 2005-03-02 康涅狄格大学 杂1,2-二氢化茚:一类新型有效的大麻配体
WO2003063781A2 (en) * 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
DE60334787D1 (de) * 2002-03-12 2010-12-16 Merck Sharp & Dohme Substituierte amide
CA2479618A1 (en) * 2002-03-26 2003-10-09 William K. Hagmann Spirocyclic amides as cannabinoid receptor modulators
US7271266B2 (en) * 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
WO2003087037A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
US7667053B2 (en) * 2002-04-12 2010-02-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
ES2301833T3 (es) 2002-07-29 2008-07-01 Hoffmann La Roche Derivados de benzodioxol.
AU2003257145B2 (en) * 2002-08-02 2008-11-13 Merck Sharp & Dohme Corp. Substituted furo (2,3-b) pyridine derivatives
CA2496097A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
AR041268A1 (es) * 2002-09-19 2005-05-11 Solvay Pharm Bv Derivados de la 1h -1,2,4- triazol-3-carboxamida que tienen actividad agonista, agonista parcial, agonista inversa o antagonista del receptor cb 1 de cannabinoide y composiciones farmaceuticas que los contienen
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
WO2004035566A1 (en) * 2002-10-18 2004-04-29 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
ITMI20022228A1 (it) * 2002-10-21 2004-04-22 Dinamite Dipharma S P A Sali di clopidogrel con acidi alchil-solforici.
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CN100360527C (zh) 2003-01-02 2008-01-09 霍夫曼-拉罗奇有限公司 Cb1受体反激动剂
MXPA05007114A (es) * 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
KR100809201B1 (ko) 2003-06-20 2008-02-29 에프. 호프만-라 로슈 아게 카나바노이드 수용체 1 역작용제로서 2-아미노벤조티아졸
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
FR2856684B1 (fr) 2003-06-26 2008-04-11 Sanofi Synthelabo Derives de diphenylpyridine, leur preparation et leur application en therapeutique
WO2005009479A1 (en) * 2003-06-30 2005-02-03 Merck & Co., Inc. Radiolabeled cannabinoid-1 receptor modulators
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
JP4527729B2 (ja) 2003-12-08 2010-08-18 エフ.ホフマン−ラ ロシュ アーゲー 新規チアゾール誘導体
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
WO2005075450A2 (en) 2004-01-28 2005-08-18 F. Hoffmann-La Roche Ag Spiro-benzodioxoles and their use as cb1 antagonists
JP2007530690A (ja) 2004-03-29 2007-11-01 メルク エンド カムパニー インコーポレーテッド 11−β−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのジアリールトリアゾール
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
BRPI0510679A (pt) 2004-05-10 2007-12-26 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
EP1781668A2 (en) 2004-07-12 2007-05-09 Cadila Healthcare Ltd. Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
JP2008509146A (ja) 2004-08-06 2008-03-27 メルク エンド カムパニー インコーポレーテッド 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのスルホニル化合物
FR2874012B1 (fr) 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique
WO2006020959A2 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
RU2394027C2 (ru) 2004-10-27 2010-07-10 Ф. Хоффманн-Ля Рош Аг Новые индольные или бензимидазольные производные
EP2127676A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP1812418B1 (en) 2004-11-09 2010-10-27 F. Hoffmann-La Roche AG Dibenzosuberone derivatives
US20080319019A1 (en) * 2004-12-23 2008-12-25 Leifeng Cheng Therapeutic Agents
WO2006067443A1 (en) * 2004-12-23 2006-06-29 Astrazeneca Ab Therapeutic agents
AU2006203845A1 (en) * 2005-01-10 2006-07-13 Alexandros Makriyannis Novel heteropyrrole analogs acting on cannabiniod receptors
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
RU2404164C2 (ru) * 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060278280A1 (en) * 2005-05-23 2006-12-14 Tzai-Jen Yang Check valve
EP1890767A2 (en) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2006136502A1 (en) * 2005-06-22 2006-12-28 F. Hoffmann-La Roche Ag ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS
CA2518579A1 (en) * 2005-08-05 2007-02-05 University Technologies International Inc. Method for appetite suppression
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
KR101318127B1 (ko) 2005-11-10 2013-10-16 엠에스디 가부시키가이샤 아자 치환된 스피로 유도체
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
WO2007106721A2 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
US20080108643A1 (en) * 2006-11-03 2008-05-08 Forest Laboratories Holdings Limited Method for treating autism
CA2673359A1 (en) 2006-12-18 2008-06-26 7Tm Pharma A/S Cb1 receptor modulators
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
PE20090142A1 (es) * 2007-04-11 2009-02-19 Merck & Co Inc Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PT2176208E (pt) * 2007-07-30 2015-05-11 Zynerba Pharmaceuticals Inc Pró-fármacos de canabidiol, composições compreendendo pró- fármacos de canabidiol e métodos de utilização dos mesmos
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
KR20100098628A (ko) * 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
BRPI0822061A2 (pt) * 2007-12-10 2015-06-23 7Tm Pharma As Moduladores do receptor canabinoide
WO2009099670A2 (en) * 2008-02-08 2009-08-13 Nektar Therapeutics Al, Corporation Oligomer-cannabinoid conjugates
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009154132A1 (ja) 2008-06-19 2009-12-23 萬有製薬株式会社 スピロジアミン-ジアリールケトオキシム誘導体
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
IT1390848B1 (it) 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
EP2149370A1 (en) * 2008-07-31 2010-02-03 Neuroscienze Pharmaness S.C. A R.L. Diazabicyclic compounds and microemulsions thereof
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009308980B2 (en) 2008-10-30 2013-02-28 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
IT1395724B1 (it) 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1394400B1 (it) * 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
DE102009035649A1 (de) * 2009-07-29 2011-02-03 Siemens Aktiengesellschaft Arzneistoff und Verfahren zur Erprobung eines Arzneistoffes
CA2779088A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
IT1396951B1 (it) * 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici
JP5540454B2 (ja) 2009-12-30 2014-07-02 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド ジペプチジルペプチダーゼ阻害剤
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
CN105001219A (zh) 2011-02-25 2015-10-28 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
JP5872591B2 (ja) * 2011-09-30 2016-03-01 ナショナル ヘルス リサーチ インスティテュートス ピラゾール化合物
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2789619A1 (en) 2013-04-12 2014-10-15 Kemotech S.r.l. Pharmaceutical compounds wiht angiogenesis inbhibitory activity
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2949559C (en) 2014-06-06 2023-08-29 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
JP2019501899A (ja) 2015-12-09 2019-01-24 リサーチ トライアングル インスティテュート 改良アペリンレセプター(apj)アゴニストおよびその使用
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
CA3119509A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase
EP3924058A1 (en) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
JP7443625B2 (ja) 2020-08-18 2024-03-05 メルク・シャープ・アンド・ドーム・エルエルシー ビシクロヘプタンピロリジンオレキシン受容体アゴニスト

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449350A (en) * 1968-06-24 1969-06-10 Ciba Geigy Corp Certain pyrazole-3-carboxylic acid hydrazide derivatives
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Similar Documents

Publication Publication Date Title
JP2000500033A5 (ja)
JP2000500445A5 (ja)
JP2000500228A5 (ja)
JP2000500440A5 (ja)
JP2000500327A5 (ja)
JP2000500145A5 (ja)
JP2000500155A5 (ja)
JP2000500406A5 (ja)
JP2000500361A5 (ja)
JP2000500115A5 (ja)
JP2000500322A5 (ja)
JP2000500258A5 (ja)
JP2000500342A5 (ja)
JP2000500192A5 (ja)
JP2000500112A5 (ja)
JP2000500226A5 (ja)
JP2000500019A5 (ja)
JP2000500397A5 (ja)
JP2000500051A5 (ja)
JP2000500407A5 (ja)
JP2000500125A5 (ja)
JP2000500166A5 (ja)
JP2000500257A5 (ja)
JP2000500090A5 (ja)
JP2000500346A5 (ja)